Table 2. Chemotherapy regimens used in newly diagnosed and relapsed/refractory multiple myeloma patients.

Regimen Abbreviation	Regimen combinations	Newly diagnosed patients, n = 25 (%)	Relapsed/ refractory patients, n = 76 (%)	Total myeloma patients n = 101 (%)
D-Rd	daratumumab, lenalidomide, dexamethasone	8 (32%)	30 (39.5%)	38 (37.6%)
D-Vd	daratumumab, bortezomib, dexamethasone	4 (16%)	19 (25%)	23 (22.8%)
D-Pd	daratumumab, pomalidomide, dexamethasone	0	6 (7.9%)	6 (5.9%)
D-Kd	daratumumab, carfilzomib, dexamethasone	0	5 (6.6%)	5 (5%)
D-VTd	daratumumab, bortezomib, thalidomide, dexamethasone	5 (20%)	0	5 (5%)
D-VRd	daratumumab, bortezomib, lenalidomide, dexamethasone	3 (12%)	1 (1.3%)	4 (4%)
D-VCd	daratumumab, bortezomib, cyclophosphamide, dexamethasone	2 (8%)	1 (1.3%)	3 (3%)
D-Id	daratumumab, ixazomib, dexamethasone	0	1 (1.3%)	1 (1%)
D-VMP	daratumumab, bortezomib, melphalan, prednisolone	1 (4%)	0	1 (1%)
D-VRD-PACE	daratumumab, bortezomib, lenalidomide, dexamethasone, cisplatin, doxorubicin, cyclophosphamide, and etoposide	1 (4%)	0	1 (1%)
D-Td	daratumumab, thalidomide, dexamethasone	0	2 (2.6%)	2 (2%)
D	Daratumumab monotherapy	1 (4%)	11 (14.5%)	12 (11.9%)